[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"active-juvenile-psoriatic-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:active-juvenile-psoriatic-arthritis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100424258","phase-3-apremilast-pediatric-study-in-children-with-active-juvenile-psoriatic-arthritis-100424258",false,"NCT04804553","Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis","A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)","PEAPOD","Inclusion Criteria:\n\n* Male or Female participants 5 to \\\u003C 18 years of age at the time of randomization.\n* Participant must have a confirmed diagnosis of juvenile psoriatic arthritis (JPsA) according to the International League of Associations for Rheumatology (ILAR) Edmonton Revision (Petty, 2001) classification criteria of at least 6 months duration:\n\n  * Arthritis and psoriasis, OR\n  * Arthritis with at least 2 of the following:\n  * Dactylitis\n  * Nail pitting or onycholysis\n  * Psoriasis in a first-degree relative\n* Active disease: at least 3 active joints.\n* Inadequate response (at least 2 months) or intolerance to ≥ 1 disease-modifying anti-rheumatic drugs (DMARD), (which may include methotrexate \\[MTX\\] or biologic agents).\n\nExclusion Criteria:\n\n* Exclusions per ILAR Edmonton Revision (Edmonton, 2001) criteria for JPsA include:\n\n  * Arthritis in an HLA-B27-positive male with arthritis onset after 6 years of age\n  * Ankylosing spondylitis, sacroiliitis with inflammatory bowel disease, Reiter's syndrome, acute anterior uveitis, or a history of one of these disorders in a first-degree relative\n  * History of IgM rheumatoid factor on at least 2 occasions at least 3 months apart\n  * Presence of systemic juvenile idiopathic arthritis (JIA).\n* Rheumatic autoimmune disease other than psoriatic arthritis (PsA), including, but not limited to: systemic lupus erythematosus, mixed connective tissue disease, scleroderma, polymyositis, or fibromyalgia.\n* Prior history of or current inflammatory joint disease other than PsA (eg, gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease).","ALL","5 Years","17 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.",[28],"Active Juvenile Psoriatic Arthritis",[30,31,32,33],"Apremilast","Otezla®","Juvenile psoriatic arthritis","Inflammatory disorders","RECRUITING","2026-08-05",{"date":37,"type":38},"2026-08-06","ACTUAL",{"date":40,"type":38},"2022-03-17",{"date":42,"type":22},"2028-12-29",{"name":44,"class":45},"Amgen","INDUSTRY",45]